Literature DB >> 21801803

Biomarkers and evolution in Alzheimer disease.

Stanley I Rapoport1, Peter T Nelson.   

Abstract

Brain regions and their highly neuroplastic long axonal connections that expanded rapidly during hominid evolution are preferentially affected by Alzheimer disease. There is no natural animal model with full disease pathology (neurofibrillary tangles and neuritic amyloid plaques of a severity seen in Alzheimer's disease brains). Biomarkers such as reduced glucose metabolism in association neocortex, defects in long white matter tracts, RNA neurochemical changes, and high CSF levels of total and phosphorylated tau protein, which are helpful to identify MCI and preclinical Alzheimer disease patients, may also provide insights into what brain changes led to this disease being introduced during hominid evolution. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801803      PMCID: PMC5878862          DOI: 10.1016/j.pneurobio.2011.07.006

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  47 in total

Review 1.  Genetic links between brain development and brain evolution.

Authors:  Sandra L Gilbert; William B Dobyns; Bruce T Lahn
Journal:  Nat Rev Genet       Date:  2005-07       Impact factor: 53.242

Review 2.  Probing the biology of Alzheimer's disease in mice.

Authors:  Karen H Ashe; Kathleen R Zahs
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

Review 3.  The brain's visual world: representation of visual targets in cerebral cortex.

Authors:  J H Maunsell
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

4.  Evolutionary trends in limbic structures.

Authors:  H Stephan
Journal:  Neurosci Biobehav Rev       Date:  1983       Impact factor: 8.989

5.  Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease.

Authors:  S J Teipel; H Hampel; P Pietrini; G E Alexander; B Horwitz; E Daley; H J Möller; M B Schapiro; S I Rapoport
Journal:  Arch Neurol       Date:  1999-04

6.  Cytoskeletal alterations might account for the phylogenetic vulnerability of the human brain to Alzheimer's disease.

Authors:  P L Di Patre
Journal:  Med Hypotheses       Date:  1991-02       Impact factor: 1.538

Review 7.  Structural correlates of cognition in dementia: quantification and assessment of synapse change.

Authors:  S T DeKosky; S W Scheff; S D Styren
Journal:  Neurodegeneration       Date:  1996-12

8.  Adaptive evolution of ASPM, a major determinant of cerebral cortical size in humans.

Authors:  Patrick D Evans; Jeffrey R Anderson; Eric J Vallender; Sandra L Gilbert; Christine M Malcom; Steve Dorus; Bruce T Lahn
Journal:  Hum Mol Genet       Date:  2004-01-13       Impact factor: 6.150

9.  Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1996-08       Impact factor: 17.088

Review 10.  Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.

Authors:  Lap Ho; Hayley Fivecoat; Jun Wang; Giulio Maria Pasinetti
Journal:  Exp Gerontol       Date:  2009-09-29       Impact factor: 4.032

View more
  14 in total

Review 1.  Post-transcriptional regulatory elements and spatiotemporal specification of neocortical stem cells and projection neurons.

Authors:  E M DeBoer; M L Kraushar; R P Hart; M-R Rasin
Journal:  Neuroscience       Date:  2013-05-30       Impact factor: 3.590

2.  The Roots of Alzheimer's Disease: Are High-Expanding Cortical Areas Preferentially Targeted?†.

Authors:  Anders M Fjell; Inge K Amlien; Markus H Sneve; Håkon Grydeland; Christian K Tamnes; Tristan A Chaplin; Marcello G P Rosa; Kristine B Walhovd
Journal:  Cereb Cortex       Date:  2014-03-21       Impact factor: 5.357

3.  Microglia changes associated to Alzheimer's disease pathology in aged chimpanzees.

Authors:  Melissa K Edler; Chet C Sherwood; Richard S Meindl; Emily L Munger; William D Hopkins; John J Ely; Joseph M Erwin; Daniel P Perl; Elliott J Mufson; Patrick R Hof; Mary Ann Raghanti
Journal:  J Comp Neurol       Date:  2018-11-16       Impact factor: 3.215

Review 4.  The Exceptional Vulnerability of Humans to Alzheimer's Disease.

Authors:  Lary C Walker; Mathias Jucker
Journal:  Trends Mol Med       Date:  2017-05-05       Impact factor: 11.951

Review 5.  Commentary: is Alzheimer's disease uniquely human?

Authors:  Caleb E Finch; Steven N Austad
Journal:  Neurobiol Aging       Date:  2014-10-23       Impact factor: 4.673

6.  Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease.

Authors:  Yunqi Xu; Xiaobo Wei; Xu Liu; Jinchi Liao; Jiaping Lin; Cansheng Zhu; Xiaochun Meng; Dongsi Xie; Dongman Chao; Albert J Fenoy; Muhua Cheng; Beisha Tang; Zhuohua Zhang; Ying Xia; Qing Wang
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

Review 7.  What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus.

Authors:  Anders M Fjell; Linda McEvoy; Dominic Holland; Anders M Dale; Kristine B Walhovd
Journal:  Prog Neurobiol       Date:  2014-02-16       Impact factor: 11.685

8.  A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls.

Authors:  Sébastien S Hébert; Wang-Xia Wang; Qi Zhu; Peter T Nelson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  Aged chimpanzees exhibit pathologic hallmarks of Alzheimer's disease.

Authors:  Melissa K Edler; Chet C Sherwood; Richard S Meindl; William D Hopkins; John J Ely; Joseph M Erwin; Elliott J Mufson; Patrick R Hof; Mary Ann Raghanti
Journal:  Neurobiol Aging       Date:  2017-08-01       Impact factor: 4.673

10.  Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease.

Authors:  Papan Thaipisuttikul; James E Galvin
Journal:  Clin Pract (Lond)       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.